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Abstract
Background: Syphilis remains a global public health threat and can lead to severe complications. In addition to
resolution of clinical manifestations, a reduction in nontreponemal antibody titers after treatment is regarded as “proof
of cure.” However, some patients manifest < 4-fold decline (“serological non-response”) or persistently positive
nontreponemal titers despite an appropriate decline (“serofast”) that may represent treatment failure, reinfection, or a
benign immune response. To delineate these treatment phenomena, we conducted a systematic review of the
literature regarding serological outcomes and associated factors among HIV-infected and -uninfected subjects.
Methods: Six databases (PubMed, Embase, CINAHL, Web of Science, Scopus, and BIOSIS) were searched with no date
restrictions. Relevant articles that evaluated serological treatment responses and correlates of serological cure (≥ four-
fold decline in nontreponemal titers) were included.
Results: We identified 1693 reports in the literature, of which 20 studies met selection criteria. The median proportion
of patients who had serological non-response was 12.1 % overall (interquartile range, 4.9–25.6), but varied depending
on the time points after therapy. The serofast proportion could only be estimated from 2 studies, which ranged from
35.2–44.4 %. Serological cure was primarily associated with younger age, higher baseline nontreponemal titers, and
earlier syphilis stage. The relationship between serological cure and HIV status was inconsistent; among HIV-infected
patients, CD4 count and HIV viral load was not associated with serological cure.
Conclusions: Serological non-response and the serofast state are common syphilis treatment outcomes, highlighting
the importance of determining the immunological and clinical significance of persistent nontreponemal antibody titers
after therapy.
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Background
Syphilis is an ancient infectious disease, yet modern ef-
forts to control the disease remain ineffective in many
countries, especially among high risk populations like
men who have sex with men (MSM) [1–3]. The World
Health Organization (WHO) estimated that in 2008, there
were 36 million prevalent cases of syphilis and 11 million
incident cases in adults between the ages of 15 and 49 [4].
Although the majority of cases have occurred in under-
developed regions like Sub-Saharan Africa, countries like
China and Russia have witnessed alarming increases in
syphilis rates attributed in part to societal and economic
changes [5, 6]. A significant association exists between
syphilis and increased risk of HIV acquisition, with hazard
ratios ranging from 2.3 to 8.6 [7–9]. A recent review of
studies conducted worldwide reported a 9.5 % prevalence
of syphilis among adults living with HIV infection [10].
Syphilis has been associated with protean clinical man-
ifestations, making reliance upon laboratory diagnosis
critical for the practicing physician. However, due to our
inability to cultivate the causative agent of syphilis in
vitro, most testing for syphilis relies on measurement of
immune responses rather than on direct tests for Trepo-
nema pallidum [11]. Direct detection methods are avail-
able for early syphilitic lesions, but polymerase chain
reaction (PCR) assays have limited sensitivities for de-
tecting spirochetes from blood, especially during latent
infection [12, 13]. Testing for syphilis involves sero-
logical assays based on nontreponemal and treponemal
antibody responses induced by T. pallidum. Nontrepo-
nemal tests measure IgM and IgG antibodies to lipoidal
antigens, principally cardiolipin, released from damaged
host cells and/or T. pallidum [11, 14]. Nontreponemal
antibody tests are still primarily used for syphilis screen-
ing in the United States (U.S.) and developing countries,
and to monitor serological response to treatment since
titers are observed to decline after effective therapy.
Treponemal assays, on the other hand, measure specific
IgM and IgG antibodies to T. pallidum proteins and
have been traditionally utilized to confirm reactive non-
treponemal tests.
Since 1993, U.S. treatment guidelines have regarded a
four-fold (or two dilution; e.g., 1:64 to 1:16) decline in
nontreponemal antibody titers or seroreversion to nega-
tive as an indicator of an appropriate serological re-
sponse after treatment [15, 16]. This recommendation
was based on a study by Brown, et al. [17], in which the
investigators generated curves demonstrating a four-fold
decline in Venereal Disease Research Laboratory (VDRL)
titers at three months following therapy, using data from
patients who had symptom resolution after treatment of
primary (PS) and secondary syphilis (SS). However, some
patients in clinical practice do not follow the classical
patterns of serological response to therapy, exhibiting
less than a four-fold decline in nontreponemal titers and/
or persistently low positive titers without evidence of
treatment failure or reinfection. These conditions have
been referred to as “serological failure,” “serological non-
response,” “seroresistance,” “reagin-fast,” or the “serofast
state.”
In addition to the lack of consensus regarding the ter-
minology used to refer to nontreponemal antibody titers
that do not meet exhibit an appropriate serological re-
sponse after therapy, there is also uncertainty regarding
whether these conditions indicate persistent infection or a
residual immune response in the absence of viable organ-
isms. Although retreatment may be beneficial for some of
these patients, there are no specific markers that can dif-
ferentiate those requiring additional therapy to prevent
subsequent sequelae. Untreated or inadequately treated
syphilis can result in severe neurological and cardiovascu-
lar complications, stillbirth, neonatal death, and irrevers-
ible congenital abnormalities [18, 19]. Not surprisingly,
considerable controversy exists whether patients who do
not demonstrate an appropriate serological treatment
response should undergo lumbar punctures to evaluate
for neurosyphilis or be retreated.
A large number of studies have been conducted to in-
vestigate serological responses after treatment of syphilis
in HIV-infected and HIV-uninfected individuals. There-
fore, we performed a systematic review to evaluate the fre-
quency of serological outcomes following syphilis therapy
and correlates associated with serological cure. This re-
view illustrates the extensive observational data that have
accrued regarding lack of serological cure after treatment,
and highlights the need for more definitive studies regard-
ing the immunological and clinical significance of persist-
ent nontreponemal antibodies over time. We hypothesize
that these persistent antibodies are associated with a fail-
ure of immune tolerance rather than lack of pathogen
clearance after recommended therapies.
Methods
Search strategy and selection criteria
A systematic review of the literature was conducted on
original research articles using the terms “syphilis” and
“serology” and “failure”, “resistance”, “response”, “serofast”,
or “seroresistance” in PubMed, Embase, Cumulative Index
to Nursing and Allied Health, Web of Science, Scopus,
and BIOSIS with no date restrictions. In addition, the
metaRegister of controlled trials (www.controlled-trials.-
com) and the U.S. National Institutes of Health Ongoing
Trials Register (www.clinicaltrials.gov) were searched for
ongoing clinical trials. The search was last updated on
November 14, 2014. In addition, syphilis experts were con-
tacted to identify other potential manuscripts. Authors of
relevant articles were contacted for further information as
needed. This literature review was registered in PROSPERO
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(CRD42013005016). The search was conducted according
to Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines. The full search strat-
egy and PRISMA checklist are included as Additional file 1.
Study selection
A database search was performed for English language
research articles, reports, abstracts, and clinical trials re-
lated to the serological outcome of syphilis treatment in
adults. Articles were first examined and selections were
made based on titles. The abstracts of these articles were
then examined for relevance to the outcomes of interest
and full text articles were reviewed. The full citation
screening process is detailed using the PRISMA flow
diagram in Fig. 1.
Eligibility criteria, data abstraction, and analysis
Articles that defined and evaluated serological out-
comes after syphilis therapy among HIV-infected and/
or -uninfected patients were included in the review.
Studies were excluded if study design and serological out-
comes were not clearly defined in the methods, if the
study only included serological non-responders without a
comparison group, or if serological outcomes could not be
estimated in the results due to combined categories (e.g.
serological non-responders with treatment failures or
reinfections).
Serological cure was defined as a ≥ four-fold decline
(at least two titers, such as 1:64 to 1:16) in nontrepone-
mal titers or seroreversion to nonreactive results after
therapy. The presence of persistent nontreponemal anti-
body titers were delineated into two categories distinct
from treatment failure or reinfection: (1) “serological
non-response” defined as < four-fold decline in nontre-
ponemal antibody titers at ≥ six months after treatment
for early syphilis or ≥ 12 months following treatment of
late latent syphilis, OR (2) “serofast status” defined as
persistently positive low-level nontreponemal antibody
Fig. 1 PRISMA flow diagram of the systematic review process using the terms “syphilis” and “serology” and “failure”, “resistance”, “response”, “serofast”,
or “seroresistance” in six databases
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titers without seroreversion after initial ≥ 4-fold decline.
Treatment failure was defined as a ≥ four-fold rise in
nontreponemal titers after treatment in the absence of
reinfection. Reinfection was defined as a ≥ four-fold rise
in nontreponemal titers after treatment, supported by a
history of having had unprotected sex with a potentially
infected person. The primary outcome was the propor-
tion of study subjects identified with serological non-
response at 6 and ≥ 12 months from therapy and clinical
correlates of serological cure. Secondary outcomes were
the proportions reported as serofast, treatment failures
or reinfections, and correlates associated with serological
response.
The following characteristics of each study were ab-
stracted: study period, sample size, study population, study
location, study design, percentage of males and MSM,
prior history of syphilis, HIV prevalence, syphilis stages,
and neurosyphilis prevalence based on cerebrospinal fluid
(CSF) analysis. Data abstraction was also performed for
the following information on diagnosis, treatment, and
serological outcomes: type of nontreponemal antibody
test; main and alternative treatment regimens; proportion
with serological cure, serological non-response, serofast
state, treatment failure, and reinfection; and correlates of
serological cure. Data abstraction was performed twice in-
dependently and there was >95 % concordance. Conflict-
ing data were resolved by a third independent individual.
A qualitative synthesis of the data was performed, and
the median and interquartile range for serofast frequency
was calculated. Meta-analysis was not feasible due to het-
erogeneity in the reporting of serological outcomes.
Quality assessment
The STROBE checklist [20] was used to assess the qual-
ity of the observational studies included in our literature
review. These evaluations are included in the Additional
file 2: Table S1.
Results
Study characteristics
We identified 1526 unduplicated articles in the literature
and reviewed 291 abstracts. Twenty articles were in-
cluded in our systematic review (Fig. 1), of which 12
were retrospective studies [21–32] and eight were pro-
spective in design [33–40]. The retrospective studies
were based on review of clinical records from patients
for whom baseline and follow-up nontreponemal anti-
body titers were available. The prospective studies in-
cluded five observational studies [33–35, 39, 40], and
three randomized controlled trials (RCTs) [36–38].
The characteristics of the study populations from these
articles are summarized in Table 1. The age of study
subjects ranged from 18–71 years; one study involved
only women [33] while 12 studies included >50 % men.
In four studies, the majority (>94 %) of subjects were
identified as MSM [25, 32, 39, 40]. The studies involved
patients from 13 diverse countries worldwide (Table 1).
Three of the prospective investigations were multicenter
studies, each of which included eight separate clinical
sites for enrollment [37, 38, 40].
Ten studies enrolled only subjects with early syphilis
(ES) [25, 27, 29, 30, 32, 36–40], which corresponded to
PS, SS, or early latent syphilis (ELS); one study evaluated
only subjects with late latent syphilis (LLS) [22]. Six
studies involved subjects with LLS, tertiary syphilis and/
or neurosyphilis at time of treatment [22–24, 26, 28, 35,
37], and three did not specify subjects’ stage of syphilis
in their study [21, 33, 34]. Two of the six studies [24, 37]
classified neurosyphilis in their patients based on CSF
markers including an elevated protein, white blood cell
count and/or a reactive CSF VDRL assay, while the
others used only a reactive CSF VDRL or did not specify
the CSF criteria for diagnosis.
Fifteen studies included HIV-infected patients with syph-
ilis in their analyses, of which six focused entirely on the
serological response to syphilis therapy among study
subjects with HIV infection [24, 25, 28, 32, 39, 40]. Subjects
from the studies which included only HIV-infected patients
had mean CD4 counts ranging from 280–565 cells/μL and
mean plasma viral loads ranging from 2.21–3.10 log10 cop-
ies/mL [32, 39]; their median HIV RNA levels ranged from
< 400 to 8742 copies/mL [24, 25]. The proportion of HIV-
infected patients who were on antiretroviral therapy (ART)
ranged from 60–87 % [25, 40].
Among the 20 studies, 2.4 million units of benzathine
penicillin (PCN) G administered intramuscularly once or
weekly for three weeks was reported as the main treatment
regimen (Table 2). However, several alternative treatment
regimens were provided to study subjects, including azi-
thromycin, doxycycline, erythromycin, tetracycline and
other PCN formulations. The RCT by Rolfs, et. al. [37] ran-
domized ES patients to receive 2.4 million units of ben-
zathine PCN with or without an enhanced regimen
consisting of a 10 day course of amoxicillin and
probenecid.
Most of the studies used the Rapid Plasma Reagin
(RPR) as the nontreponemal test to monitor serological
response. There were, however, variations in the length
of follow-up after treatment ranging from six months to
five years (Table 2). One retrospective study reported a
median follow-up time of 5.3 years [24]. For the pro-
spective studies, retention rates for study subjects ranged
from 61–94 % at six months and 52–81 % at 12 months
after enrollment [36–40].
Definitions and time points after therapy
Although all of the studies defined an appropriate sero-
logical response as a ≥ four-fold decline in nontreponemal
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Table 1 Study design and characteristics of the study population among 20 studies included in the systematic review
First author Study
design
Study
time
period
Study location Number
of study
subjects
Study
population
Male
sex
(%)
Men who
have sex
with men
(%)
HIV
prevalence
(%)
Primary
syphilis
(%)
Secondary
syphilis (%)
Early
latent
syphilis
(%)
Late
latent
syphilis
(%)
Tertiary or
neuro-
syphilis
(%)
Dionne-
Odom
R
cohort
2002–
2008
Lusaka, Zambia and Kigali, Rwanda 1321 HIV-
serodiscordant
couples
40 NR 70.6 NR NR NR
Fiumara R
cohort
NR Boston, Massachusetts (US) 128 University
hospitals
64 NR NR 0 0 0 100 NR
Ghanem
(2007) [23]
R
cohort
1992–
2000
Baltimore, Maryland (US) 297 STD clinic 44 NR 43.4 62.6 37.4 0
Ghanema
(2008) [24]
R
cohort
1990–
2006
Baltimore, Maryland (US) 180 University HIV
clinic
67.2 NR 100 26.8b 55.4b 17.8b
Goemenb P
cohort
NR Kinshasa, Zaire 193 Women’s
health center
0 0 37 NR NR NR
Jinno R
cohort
2006–
2011
Los Angeles, California (US) 560 Urban HIV
clinics
99 96.7 100 14 26 60 0 0
Knautec R
cohort
1999–
2008
Zurich, Switzerland 264 University and
general
hospitals
92 NR 42 34 50 13d 3
Li R
cohort
2000–
2010
Beijing, China 501 University
hospital
50.9 NR 0 17.4 51.1 31.5 0 0
Longe P
cohort
2003 Lima, Peru 96 Neighborhood
venues
NR NR 15.6 NR NR NR
Malonef R
cohort
1985–
1991
San Diego, California (US) 100 Naval Medical
Center
99e NR 100 3.6 16.1 17.9 53.6 8.9
Manavig P
cohort
2003–
2005
Birmingham UK 261 STD clinics 76f 38.3 38.3 0 0 100 0 0.4
Reidner P RCT 2000–
2003
Myeba Region, Tanzania 328 High risk
populations
28.4 NR 52.1 7.6 0 92.8 0 0
Rolfs P RCT 1991–
1994
NR 541 NR 70.8 12.8 18.7 25.7 46.8 27.5 0 HIV+:
61 %
HIV-: 40 %
Romanowski R
cohort
1981–
1987
Alberta, Canada 882 Provincial
public health
records
17 21.1 NR 68.3 18.3 4.3 0 NR
Seña P RCT 2000–
2009
Birmingham New Orleans, Los Angeles,
Baltimore, Durham, Raleigh, Indianapolis, (US);
Antana-narivo Tamatave, Madagascar
465 STD clinics 61.7 3.0 0 24.7 46.9 28.4 0 0
Tittesh R
cohort
1987–
2010
Vienna, Austria 249 University STD-
outpatient
clinic
83.1 31.7 26.1 73.9 0 0 0
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Table 1 Study design and characteristics of the study population among 20 studies included in the systematic review (Continued)
Tong R
cohort
2005–
2010
Xiamen, China 1327 University
hospital
58.9 NR 0 22.0 27.1 31.4i 19.5d
Tsai R
cohort
2007–
2013
Taiwan 394 HIV care
hospitals
100 94.9 100 8.9 55.3 35.8 0 0
Wuj P
cohort
2009–
2013
Taiwan 174 University
hospital
99.7 97.0 100 17.6 53.7 28.7 0 0
Yang P
cohort
2007–
2012
Taiwan 573 HIV care
hospitals
NR 94.1 100 8.9 57.8 33.3 0 0
R retrospective, P prospective, RCT randomized controlled trial, NR not reported
a Demographics and serological outcome data were reported for 180 patients; however, syphilis stages were reported for 231 cases of syphilis
b Demographics were reported for 193 patients; however, serological outcome data were reported for 120 patients
c Demographics and syphilis stages were reported for 264 patients; however, serological outcome data were reported for 214 patients
d This value is the total percentage of latent syphilis patients. This study did not distinguish between early latent and late latent patients
e Demographics were reported for 96 patients; however, serological outcome data were reported for 76 patients
f Demographics and syphilis stages were reported for 100 patients; however, serological outcome data were reported for 56 patients
g Demographics and syphilis stages were reported for 371 patients; however, serological outcome data were reported for 261 patients
h Demographics and syphilis stages were reported for 379 patients; however, serological outcome data were reported for 249 patients
i This value is the total percentage of latent syphilis patients. This study did not distinguish between early latent and late latent patients
j Demographics and syphilis stages were reported for 296 patients; however, serological outcome data were reported for 174 patients
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Table 2 Syphilis treatment regimens, nontreponemal antibody tests, estimated proportions with serological cure and serological
non-response at time points after therapy
First Author Main syphilis
treatment
regimens
Alternative syphilis
treatment regimens
Non-
treponemal
antibody
test
% Serological cure (≥ 4-fold
decline in nontreponemal
titers or seroreversion)
% Serological non-response
(< 4-fold decline in
nontreponemal titers)
Time
period
assessed
after
therapy
Dionne-
Odom
1–3 doses benzathine
PCN G (2.4 MU IM
weekly)
None RPR 66.8 26.6 400 days
Fiumara 2 doses benzathine PCN
G (2.4 MU IM weekly)
Tetracycline RPR 64.1 33.6 < 5 years
Ghanem
(2007) [23]
Benzathine PCN G (1
dose for early syphilis, 3
doses for late syphilis)
Doxycycline RPR 87.9 9.1 400 days
Ghanem
(2008) [24]
Benzathine PCN G (1
dose for early syphilis, 3
doses for late syphilis)
Doxycycline RPR 60.5 14.4 9–12
monthsa
Goemen 3 doses benzathine PCN
G (2.4 MU IM weekly)
None RPR 23.4 71.3 6 months
27.5 62.5 12
months
40.0 56.7 24
months
Jinno 1–3 doses benzathine
PCN G (2.4 MU IM
weekly)
Doxycycline RPR 90.9 9.1 9–12
months
Knaute 1–3 doses benzathine
PCN G (2.4 MU IM
weekly); aqueous PCN G
for tertiary syphilis
None VDRL 96.3 3.7 6 months
97.7 2.3 9 months
99.1 0.9 12–18
months
Li 2 doses benzathine PCN
G (2.4 MU IM weekly)
Not reported RPR 85.0 15.0 6 months
Long 1–3 doses benzathine
PCN G (2.4 MU IM
weekly)
Doxycycline RPR 93.4 6.6 12
months
Malone 3 doses benzathine PCN
G (2.4 MU IM weekly)
PCN G procaine with
probenecid or IV PCN
G
VDRL 79.8 2.3 12
months
Manavi 1–3 doses benzathine
PCN G (2.4 MU IM
weekly)
Doxycycline for 21
days
VDRL 68.2 31.4 12
months
Reidner 1 dose benzathine PCN
(2.4 MU IM)
Azithromycin RPR 96.4 3.6 9 months
Rolfs 1 dose benzathine PCN
(2.4 MU IM)
1 dose benzathine
PCN enhanced with 10
day course of
amoxicillin and
probenecid
RPR 89.3 10.7 6 months
90.3 9.7 12
months
Romanowski 1 dose benzathine PCN
(2.4 MU IM)
Tetracycline or
erythromycin
RPR 77.9 22.1 6 months
88.8 11.2 12
months
95.1 4.9 24
months
Seña 1 dose benzathine PCN
(2.4 MU IM) or
azithromycin (2g PO)
Doxycycline RPR 78.5 20.5 6 months
Tittes 1–3 doses benzathine
PCN (2.4 MU IM weekly)
None VDRL 95.2 4.8 6 months
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antibody titers after treatment, there were differences in
the terminology used to refer to a < 4-fold decline in non-
treponemal titers following therapy. Several investigators
referred to or grouped these outcomes with treatment fail-
ures (i.e. a 4-fold rise in titers) [23, 24, 28, 32, 35, 37]. Four
studies used the term “serofast state” to refer to serological
non-responders [21, 27, 30, 38]. Accordingly, we redefined
the data and results from these studies using our criteria
for serological outcomes (see Methods).
There were differing time points after therapy at which
serological outcomes were determined, but which were
generally consistent with clinical guidelines for monitor-
ing [41]. Four studies reported only on the proportion of
ES patients who met serological outcomes at six months
[27, 28, 38, 39]. The other studies determined their out-
comes at varied time points for other stages of infection
(e.g. nine-12 months, 12 months, 400 days). The retro-
spective study by Romanowski, et al. [29] analyzed the
most time points after treatment (i.e., at six, 12, and 24
months) for changes in RPR titers from baseline among
1090 ES patients.
Frequency of serological outcomes after therapy
Among the 20 studies included in our review, the median
proportion of patients who had serological non-response
after treatment was 12.1 % overall (interquartile range
[IQR]: 4.9 – 25.6). At six months, the median proportion
of patients who were serological non-responders following
therapy was 20.5 % (IQR: 8.2 - 25.6). This proportion
decreased to 11.2 % (IQR: 5.8 – 31.9) at ≥ 12 months for
all stages of syphilis. Using data from the 10 studies that
included only ES patients, the median proportion of sero-
logical non-response was 9.4 % (IQR: 4.8 – 19.1); only one
study by Fiumara [22] was restricted to LLS patients, for
which the proportion with serological non-response was
estimated at 21.1 %. Very few studies in our review
provided estimates of the proportion of patients who had
a ≥ 4-fold decline in nontreponemal antibody titers after
treatment but remained serofast over time; the estimated
proportion was 35.2 % in the study by Fiumara [22]
among patients with LLS, and 44.4 % in the cohort
reported by Ghanem, et al. [24] among HIV-infected pa-
tients with both ES and late syphilis [24].
Five studies reported treatment failures, which met the
definitions for a ≥ four-fold rise in nontreponemal titers
after treatment in the absence of reinfection; the propor-
tion reported from these studies ranged from 0–24 % [23,
24, 28, 33, 37]. Ghanem, et al. [24] reported the highest
proportion of treatment failures among 44/180 of HIV-
infected patients; however, the investigators acknowledged
the difficulty in distinguishing between treatment failures
and reinfections in the absence of behavioral or network
data. Seven studies reported reinfections among their
syphilis patients, with estimates ranging from 0.2–10 %
[21, 23, 26, 32, 35, 37, 40].
Association of serological outcomes with patient
demographics
Ten studies assessed the association of patient age with
serological response to therapy (Table 3). Five found that
younger age was significantly associated with serological
cure [24, 30–32, 38], and the other five reported no
association [25, 29, 35, 39]. In a retrospective study of
1327 HIV-negative persons, Tong, et al. [31] found that
patients < 23 years of age had a 2.2 adjusted odds ratio
(AOR) (95 % CI: 1.1–4.2) for serological cure compared
to those > 40 years. Tsai et al. [32] demonstrated that
HIV-infected patients aged < 34 who received benzathine
PCN were twice as likely to achieve serological cure at 6
months after treatment compared to older HIV-infected
individuals. Regarding gender, only two of five studies
found a significant association with serological out-
comes. Tong et al. [31] reported that serological cure
was associated with male sex, while Dionne-Odom, et al.
[21] noted an association with female sex.
Table 2 Syphilis treatment regimens, nontreponemal antibody tests, estimated proportions with serological cure and serological
non-response at time points after therapy (Continued)
Tong 1–3 doses benzathine
PCN (2.4 MU IM weekly)
Azithromycin IM or IV RPR 64.1 35.9 6 months
65.6 34.4 12
months
Tsai 1 dose benzathine PCN
(2.4MU IM)
Doxycycline RPR 69.5 25.9 6 months
67.8 32.3 12
months
Wu 1 dose benzathine PCN
or azithromycin
3 doses of benzathine
PCN or doxycycline
RPR 74.7 25.3 6 months
Yang 1–3 doses benzathine
PCN (doses NR)
None RPR 79.1 5.6 6 months
70.9 4.2 12
months
PCN penicillin, MU million units, IM intramuscular, IV intravenous, RPR rapid plasma reagin, VDRL venereal disease research laboratory; NR not reported
a Serological outcomes were determined at ≥ 9 months after treatment for early syphilis or ≥ 12 months for late syphilis
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Association of serological outcomes with baseline
nontreponemal antibody titers
Thirteen studies evaluated the association of baseline
nontreponemal antibody titers with serological treat-
ment response. Of these, ten found that higher baseline
titers (e.g., ≥ 1:32) were significantly associated with a
greater likelihood of or time to serological cure in both
HIV-infected and HIV-uninfected patients (Table 3) [21,
23, 25, 27, 29–31, 34–36, 38]. Tong, et al. [31] reported
that a baseline titer ≤ 1∶2 or ≥ 1∶64 was associated with
an increased likelihood of serological cure among pa-
tients with PS, SS, latent and tertiary syphilis. In con-
trast, Romanowski, et al. [29] reported that lower
baseline titers (e.g. ≤ 1:8) in ES were associated with an
increased likelihood of seroreversion. One other study
found no association between baseline nontreponemal
titers and subsequent serological outcomes [39].
Association of serological outcomes with stage of syphilis
Twelve studies evaluated the association of syphilis stage
with serological outcomes, of which seven observed an
association between earlier stage of infection and cure
[21, 26, 27, 29, 31, 36, 38–40]. In general, there was an
increased likelihood of or time to serological cure among
patients with PS or SS compared to those with ELS. Wu,
et al. [39] reported that HIV-infected patients with ELS
had a decreased AOR of 0.32 (95 % CI 0.14–0.71) for
serological cure at 6 months after therapy compared to
patients with PS or SS. Six studies included patients with
later stages of syphilis but had limited data [22–24, 26,
28, 31]; Tong, et al. [31] did report that patients with ES
had a higher likelihood of a serological cure at 12
months (OR 2.4) compared to patients with late syphilis.
Association of serological outcomes with treatment
regimen
Nine studies evaluated the effect of treatment regimens
on serological outcomes, but only two found any signifi-
cant associations. Yang, et. al. [40] reported an increased
AOR of 1.68 (95 % CI 1.20–2.36) for serological cure with
three weekly doses of benzathine PCN compared to one
dose among HIV-infected patients with ES. However,
Table 3 Patient characteristics and other factors evaluated for their associations with serological outcomes after syphilis therapy
First Author PatientAge Patient
Gender
Baseline
nontrepo-
nemal titers
Stage of
syphilis
infection
History of
prior
syphilis
Trepo-
nemal
IgM
Syphilis
treatment
regimen
HIV
coinfection
CD4
cell
count
HIV
viral
load
Antiretroviral
therapy
Dionne-
Odom
+ + + —
Fiumara +
Ghanem
(2007) [23]
— +
Goemen —
Knaute + —
Li + + +
Long + — —
Manavi — + + — —
Reidner — — + + — —
Rolfs — — +
Romanowski — — + + +
Seña + + + — —
Tittes + — + — + —
Tong + + + +
Ghanem
(2008) [24]
+ — H + — +
Jinno — + — + — H + — —
Malone H —
Tsai + — — H — — —
Wu — — + H — — —
Yang + + — + H — — —
H indicates that the study included HIV-infected participants only
+ indicates a significant association in multivariate analyses between the variable and serological outcomes after therapy
– indicates that a significant association was not identified between the variable and serological outcomes after therapy
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Tittes, et al. [30] noted higher serological cure rates overall
with one dose of benzathine PCN compared to three doses
of weekly PCN (98 % vs. 92 %, p = 0.003) among both HIV-
infected and HIV-uninfected patients with PS or SS. In this
study, serological cure rates among HIV-infected patients
were reported to be 88 % with one PCN dose compared to
97 % with three doses, but the difference was not found to
be statistically significant (p = 0.18) [30].
Association of serological outcomes with HIV status
Nine studies evaluated the association of HIV status with
serological outcomes after treatment of syphilis by com-
paring patients with and without HIV infection. Of these
studies, only two reported that HIV-infected patients
were less likely to achieve serological cure [24, 37]; the
other seven indicated that HIV status did not affect
treatment outcomes [21, 26, 29, 33–36]. Ghanem, et al.
[23] noted that HIV-infected patients with ES had a
significantly increased risk of serological failure, and that
those with LLS had a slower response time to treatment
than HIV-uninfected patients (342 vs 138 days respect-
ively, p = 0.03). The RCT by Rolfs, et. al. [37] which
included 101 HIV-infected persons reported that pa-
tients with PS had an AOR of 7.6 (95 % CI: 1.3–44.2) for
serologic treatment failure at six months compared to
patients without HIV infection. Furthermore, multivari-
ate analysis of the mean decrease in the RPR titer
showed that PS patients co-infected with HIV had a sig-
nificantly slower titer decrease than HIV-uninfected
patients. The latter study is one of few to measure the
rate of reduction of nontreponemal antibody titers over
time. However, the differences between HIV-infected
and HIV-uninfected persons were not found to be statis-
tically significant for patients who had SS or ELS [37].
Factors associated with serological outcomes among HIV-
infected persons with syphilis
Six studies analyzed the serological response after treatment
solely among HIV-infected persons (Table 3). Ghanem, et
al. [24] reported that a CD4 cell count of < 200 cells/mL
was associated with an increased risk of serological failure
(adjusted hazard ratio, 2.5; 95 % CI: 1.3–4.9), and that use
of ART was associated with a 60 % reduction in the rate of
serological failure. Jinno, et al. [25] similarly noted that a
lower CD4 count (i.e. < 350 cells/mL) among HIV-infected
patients was significantly associated with serological failure
after treatment. However, other studies found no associ-
ation between CD4 count, HIV viral load, or ART among
participants with HIV infection [28, 30, 39, 40].
Other factors and their association with serological
outcomes
Additional factors have been evaluated for their associations
with serological outcomes following syphilis treatment
(Table 3). Seven studies assessed a prior history of syphilis,
of which three noted a significant association with treat-
ment response. Two of the studies demonstrated a lower
likelihood of cure among patients with prior syphilis infec-
tion [25, 29]; however, Manavi et al. [35] found that past
syphilis treatment was significantly associated with sero-
logical response to current therapy. Two studies noted
conflicting correlations between the detection of trepo-
nemal IgM antibodies in patients’ serum and serological
treatment response [27, 35], which is a marker for early
infection.
Lumbar punctures among patients with serologic
non-response
Only one study performed lumbar punctures among in-
dividuals with serological non-response to therapy [22].
Fiumara evaluated the CSF in six patients who did not
exhibit a four-fold decrease in nontreponemal titers after
treatment, including one individual that had a RPR titer
of 1:32 for four years. None of the patients that he evalu-
ated were found to have reactive spinal fluids suggestive
of neurosyphilis [22].
Discussion
T. pallidum cannot be cultured in vitro, thus forcing re-
liance on serological tests for diagnosis and proof of
cure. This practice has been in place for nearly a century
due to the absence of novel technologies to confirm
eradication of the organism. Unfortunately, our system-
atic review of 20 studies conducted worldwide among
HIV-infected and HIV-uninfected patients with syphilis
demonstrates that a substantial proportion (12.1 %) of
patients exhibit serological non-response after treatment,
which is time-dependent. The median proportion of
serological non-response patients was 20.5 % at six
months, which decreased to 11.2 % at ≥ 12 months for
all stages of syphilis. Our findings highlight the import-
ance of developing a consistent definition of serological
non-response, which is not an absolute or definite con-
dition but should be thought of as a continuum with
serological cure and the serofast state over time. The
presence of persistent nontreponemal antibodies may
represent treatment failure, reinfection, or another un-
defined immune phenomenon; however, none of the
studies in our review could distinguish among these pos-
sibilities when neither a four-fold rise in nontreponemal
antibody titers nor a history of re-exposure was evident.
The appropriate time to determine falling titers, and the
correlates that affect the time when titers fall, remains un-
clear. Serological cure was less likely in older individuals,
patients with lower baseline nontreponemal antibody ti-
ters, and patients with later stages of syphilis. The clinical
or biological explanations for these observations have not
been well established. Perhaps more importantly, there are
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no consistent criteria by which patients can be stratified to
determine their need for additional evaluation or syphilis
therapy when serological non-response exists.
Nontreponemal antibodies have played a pivotal role
in syphilis screening and monitoring of treatment out-
comes; yet the mechanism by which they arise is poorly
understood. The first serological test for syphilis was
developed in 1906 as a complement fixation assay by
Wasserman,et. al. [42], using antigens from human and
monkey extracts rich in T. pallidum. Other investigators
soon discovered that antibodies from syphilis patients
reacted not just with antigens from spirochetes but also
with cardiolipin found in normal nonsyphilitic tissues.
Pangborn subsequently purified cardiolipin from beef
heart extract [43], which in combination with lecithin
and cholesterol, serves as the antigen for current nontre-
ponemal antibody tests. The central question is whether
the cardiolipin antibodies detected in syphilis patients
are a response specific to the spirochete, since the lipid
composition of purified T. pallidum has been identified
as 13 % cardiolipin [14, 44]. However, individuals who
have no other evidence for syphilis infection have been
found to have anticardiolipin antibodies similar to those
detected in syphilitic patients, leading to the hypothesis
that this class of antibodies may be generated in response
to destruction of host tissues [45]. Nontreponemal anti-
bodies have been observed in persons with a variety of
infectious and autoimmune diseases including HIV, hepa-
titis, and systemic lupus erythematosus [46–48], and these
potentially false positive tests continue to cause problems
in diagnosis and management.
The possibility that persistent nontreponemal antibodies
after treatment represent persistence of T. pallidum was
raised by early investigators, based on findings from ani-
mal and human studies conducted in the 1960s [49, 50].
These studies identified treponemes in lymph nodes and
CSF of rabbits one year after therapy for LLS, and re-
ported similar findings in human subjects [49]. However,
subsequent investigations questioned whether these trepo-
nemes were viable, since the transfer of material from the
lymph nodes of some treated syphilis patients produced
no detectable disease upon inoculation into rabbits [50].
Studies of the natural history of syphilis have demon-
strated that T. pallidum can disseminate to multiple or-
gans in humans within hours of inoculation [46]. T.
pallidum is then known to infect various anatomical sites,
including the central nervous system and eye as “immune
privileged” areas where the spirochetes can slowly
replicate and evade the immune response [46]. Symp-
tomatic and asymptomatic neurosyphilis has been re-
ported in a case series of serofast patients previously
treated for ES [51]; however, the study involved only
a small number of patients and is contrary to the
findings by Fiumara [22].
In order to address the question of persisting spiro-
chetes after therapy, highly sensitive direct detection
methods for T. pallidum would be essential for analyz-
ing patient specimens before and after treatment. Unfor-
tunately, a meta-analysis of studies evaluating the
performance of T. pallidum PCR on samples taken dur-
ing different stages of infection reported pooled sensitiv-
ities as low as 31.2 % and 47.4 % in blood and CSF
specimens, respectively [52], illustrating their limitations
in ruling out residual spirochetes in previously treated
patients. In the absence of a readily available test of cure
based on detection of the organism, there is no other de-
finitive method to detect persistent T. pallidum in sero-
logical non-responders or serofast patients. This suggests
that other means, such as analysis of antigen-specific
immune responses that occur during infection and after
therapy, may be a more pragmatic approach to investigat-
ing these conditions.
The hypothesis that a lingering immune response is
responsible for persistent nontreponemal antibodies can
be argued based on a number of key observations. We
found that 11 % of patients still exhibit serological non-
response at ≥ 12 months after therapy; yet reported
tertiary syphilis cases are still relatively uncommon
worldwide. Thus, the observed proportion of serological
non-response is not likely to be associated with a high
frequency of cardiovascular or neurological complica-
tions as might be expected, given the global rate of syph-
ilis. PCN has been considered to be highly effective since
it was first reported for treatment of syphilis [53]. T. pal-
lidum is extremely sensitive to minute amounts of PCN
in vitro and in vivo if maintained for sufficient periods of
time [54, 55], and presently, there are no data to suggest
that the spirochete has developed PCN resistance. Fur-
thermore, there are no clear benefits to providing add-
itional therapy for serological non-responders or serofast
patients although they may repeatedly undergo retreat-
ment in clinical practice. A recent study involving ES
patients who had serological non-response after initial
therapy and received an additional dose of benzathine
PCN demonstrated that 73 % still failed to have an ap-
propriate serological response and only 2 % seroreverted
at 12 months despite retreatment [56]. These findings
imply that persistent nontreponemal antibody titers may
not be due to insufficient therapy, but rather an alterna-
tive process like the immune response to treponemal
infection. Presently, there have been no other studies
demonstrating that retreatment of patients who are sero-
logical non-responders leads to improved outcomes.
Treponemal IgM and IgG antibodies have already been
demonstrated to persist in syphilis patients after therapy
[57–59], indicating the presence of plasma cells that
continue to produce T. pallidum specific antibodies.
This kind of pathogen-specific memory response is seen
Seña et al. BMC Infectious Diseases  (2015) 15:479 Page 11 of 15
after both infections and vaccinations. Long-term study
of human volunteers has shown that pathogen-specific
memory responses have very slow decay rates with ap-
parent half-lives ranging from years to millennia [60].
Therefore, the persistence of treponemal antibodies is
expected despite clearance of infection after treatment.
In contrast, nontreponemal antibodies decline after
therapy in the majority of syphilis patients, indicating that
they are down-regulated after clearance of T. pallidum.
These antibodies are autoreactive since cardiolipin, the
main antigenic component that binds to nontreponemal
antibodies, is present in mitochondrial membranes. Dis-
appearance of these autoreactive antibodies after syphilis
therapy leading to seroreversion suggests the involvement
of tolerance control. In serological non-response and the
serofast state, there is an apparent failure of the expected
process for down-regulation. Persisting nontreponemal
antibodies after effective therapy may thus represent fail-
ure of immune tolerance rather than lack of pathogen
clearance. Recent work on HIV has shown that many
antibodies against the virus are autoreactive and under
tolerance controls [61–67], and careful study of these anti-
bodies has provided clues to their origin and regulation.
Understanding the nature of nontreponemal antibodies in
syphilis patients who do not have an appropriate sero-
logical response could shed light on their origins, and
allow differentiation between antibodies indicative of per-
sistent infection or mere antibody persistence in the ab-
sence of infection.
Our review found conflicting evidence on the relation-
ship between demographic, clinical factors, HIV status
and serological response. The associations of syphilis stage
and baseline nontreponemal antibody titers with sero-
logical treatment outcomes appear to be the most consist-
ent among the studies in this review. Only two out of nine
studies reported that HIV-infected status decreased the
likelihood and time to serological cure [23, 37]. Markers
of immune function such as CD4 count and HIV viral
load also do not appear to affect serological outcomes
among HIV-infected persons with syphilis [28, 32, 39, 40].
Patients with HIV infection have well described dysfunc-
tion of antibody formation [68], and the former finding
may be due to this B cell dysfunction [69] in which there
is less effective immune clearance of T. pallidum in HIV-
infected persons. The epidemiological connection between
HIV and syphilis is well-established [70, 71], but an under-
standing of the biological and immunological relationships
between these co-infections remains obscure.
Several limitations are evident from this systematic re-
view. First, there was no standard definition for sero-
logical non-response that was consistent. There was
heterogeneity in the classifications of serological out-
comes that did not meet the criteria for serological cure,
which is partly related to the lack of consensus of the
U.S. and European Union guideline definitions [41, 72].
This discordance presented challenges in the overall syn-
thesis of results, and may have affected our estimates.
Secondly, there were variations in follow-up times when
a patient was considered to have serological non-
response after treatment. Longer follow-up periods are
necessary in order to determine serological outcomes
over time; however, this must be balanced by the chal-
lenges of having patients return for serological monitor-
ing years after completion of therapy. In general, most of
the studies defined ELS as syphilis acquired < 1 year
prior according to U.S. and European CDC criteria
rather than < 2 years [41, 72]; however, there is a poten-
tial that some LLS cases were included as early cases
resulting in lower response rates due to non-
discriminatory misclassification. Only a few studies in
our review provided data on the serofast state, treatment
failures or reinfections; therefore, our estimates about
the frequency of these conditions were limited. Finally,
there has only been a handful of prospective studies to
assess serological outcomes following treatment of syph-
ilis. The majority of the studies reviewed were retro-
spective in study design, which presents disadvantages
due to the potential for selection bias and misclassifica-
tion as a result of non-standardized data collection and
follow-up periods after treatment.
Our results highlight a fundamental problem in the
management of T. pallidum infections that has prevailed
over decades. Clinicians have been taught to expect at
least a four-fold decline in nontreponemal antibody ti-
ters or seroreversion to following therapy; however, sero-
logical non-response occurs in nearly one out of every
eight patients with syphilis after treatment. This signifi-
cant proportion and our clinical observations regarding
serological non-response and the serofast state suggest
the following plausible scenarios that patients may even-
tually exhibit serological response or serorevert over
time (e.g. as in LLS); patients may be getting reinfected
at a high rate; patients may not be achieving 100 % cure
from PCN; or that patients with persistent nontrepone-
mal antibody titers have neither reinfection nor persist-
ent T. pallidum but instead, an altered immune process
in which their anticardiolipin antibodies are not down-
regulated. Given the diversity of data presented here, it
is conceivable that each of these possibilities holds true
for a subset of patients, and we presently lack sufficient
information to differentiate among these or other sce-
narios. There have been vast improvements in methods
for detection of microorganisms, and in understanding the
host response to different infections. Unfortunately, mod-
ern innovative technologies have not yet been applied to
the study of syphilis. Based on the data from our systematic
review, we do not believe that further retrospective studies
of serological response to recommended therapies will be
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useful or informative. Rather, coordinated investigations
involving novel B cell methods, direct detection assays for
T. pallidum, and correlations with nontreponemal and
treponemal antibody tests in syphilis-infected patients are
essential to advancing clinical management of this formid-
able pathogen.
Conclusions
Syphilis remains a global public health threat, whose clin-
ical management is highly dependent on nontreponemal
antibody titers. Unfortunately, the basis for the cardiolipin
antibodies detected during syphilis infection is poorly
understood, and our systematic review affirms that a
significant proportion of both HIV-infected and HIV-
uninfected patients will have serological non-response
after therapy. These patients may have reinfection, treat-
ment failure, or a benign immune response. In order to
explore these possibilities and inform clinical practice,
efforts must be directed towards designing prospective
syphilis studies and utilizing modern technologies to de-
termine the microbiological and immunological basis for
these antibodies.
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